Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.16 USD | +1.17% | -0.84% | -35.02% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.02% | 2.19B | B- | ||
-4.84% | 182B | C+ | ||
+0.56% | 110B | C | ||
-3.35% | 68.11B | A | ||
+2.39% | 50.53B | B- | ||
+9.36% | 44.8B | B- | ||
+2.70% | 40.7B | B+ | ||
+24.51% | 32.3B | B | ||
+3.43% | 26.53B | A- | ||
-0.32% | 24.96B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CNMD Stock
- Ratings CONMED Corporation